(Q46112392)

English

High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?

scientific article published on 13 November 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification? (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

1 reference

based on heuristic

inferred from title

Crohn's disease

1 reference

based on heuristic

inferred from title

author name string

Lajos Sandor Kiss

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Maria Papp

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Barbara Dorottya Lovasz

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Zsuzsanna Vegh

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Petra Anna Golovics

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Eszter Janka

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Eva Varga

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Miklos Szathmari

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Peter Laszlo Lakatos

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

publication date

13 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Inflammatory Bowel Diseases

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

18

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

1647-1654

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

Is the disease course predictable in inflammatory bowel diseases?

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Laboratory markers in IBD: useful, magic, or unnecessary toys?

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Biomarkers to improve diagnostic and prognostic accuracy in systemic infections

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohnʼs disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn’s Disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.21933

21 January 2018

Identifiers

10.1002/IBD.21933

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/22081542

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46112392&oldid=1520595823"